Vardenafil in Men with Stable Statin Therapy and Dyslipidemia
Authors:
- 1 June 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 5 (6) , 1455-1467
Abstract
Introduction: Phosphodiesterase type-5 (PDE-5) inhibitors have previously been evaluated for their efficacy and safety in various clinical trials in men with erectile dysfunction (ED) with or without associated comorbidities. Aim: This is the first prospective, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a PDE-5 inhibitor (i.e., vardenafil) in an exclusive population of men with ED and dyslipidemia. Main Outcome Measures: Three coprimary efficacy measurements (Sexual Encounter Performance [SEP]2, SEP3, International Index of Erectile Function-Erectile Function [IIEF-EF] domain scores) were used to assess the differential effect of vardenafil vs. placebo in this patient population. Adverse events (AEs) safety data were obtained to compare safety outcomes. Methods: This 12-week of randomized, double-blind, placebo-controlled study was conducted in 59 U.S. centers. Patients received either on-demand, flexible-dose vardenafil 10 mg (titrated to 5 mg or 20 mg based upon efficacy and safety) or placebo. Results: Of the 712 patients screened and entered into the study, 395 were randomized. Baseline demographics for the intent-to-treat population included: mean age, 54.4 years (±7.5 standard deviation [SD]); 76% Caucasian; mean body mass index (BMI), 31.7 kg/m2 (±12.7 SD); 47% past/present smoker; and 42% severe ED. Aside from dyslipidemia, other comorbidities included hypertension, 61%; obesity (i.e., BMI ≥ 30), 51%; and type 1 or 2 diabetes, 40%. During the 12-week treatment period, the least squares (LS) adjusted mean success rates in patients on vardenafil vs. placebo were: SEP2, 79.09% vs. 51.92%; and SEP3, 66.69% vs. 33.83% (P <0.001). The LS adjusted mean IIEF-EF domain score for week 12 using LOCF was 21.99 in patients on vardenafil therapy vs. 14.83 in those on placebo (P <0.001). The most commonly encountered AEs were headache and nasal congestion. Conclusions: Vardenafil was demonstrated to be safe and effective for managing ED in men with ED and associated dyslipidemia. The results of this study support the role of expanded research on outcomes related to effective ED treatment and aggressive lipid control.Keywords
Funding Information
- GlaxoSmithKline
This publication has 58 references indexed in Scilit:
- Efficacy and Safety of Flexible-Dose Vardenafil in Men with Type 1 Diabetes and Erectile DysfunctionThe Journal of Sexual Medicine, 2006
- Cardiovascular Safety Update of Tadalafil: Retrospective Analysis of Data from Placebo-Controlled and Open-Label Clinical Trials of Tadalafil With As Needed, Three Times-per-Week or Once-a-Day DosingThe American Journal of Cardiology, 2006
- Intracavernosal Basic Fibroblast Growth Factor Improves Vasoreactivity in the Hypercholesterolemic RabbitThe Journal of Sexual Medicine, 2006
- Erectile dysfunction and statin treatment in high cardiovascular risk patientsInternational Journal Of Clinical Practice, 2006
- Evaluating Preference Trials of Oral Phosphodiesterase 5 Inhibitors for Erectile DysfunctionEuropean Urology, 2006
- Sexual Dysfunction and Cardiac Risk (the Second Princeton Consensus Conference)The American Journal of Cardiology, 2005
- The impact of vascular risk factors on erectile functionDrugs of Today, 2005
- Vardenafil Improves Patient Satisfaction with Erection Hardness, Orgasmic Function, and Overall Sexual Experience, While Improving Quality of Life in Men with Erectile DysfunctionThe Journal of Sexual Medicine, 2004
- Erectile dysfunction and vascular diseasePostgraduate Medicine, 2003
- Intracavernosal injections of vascular endothelial growth factor protects endothelial dependent corpora cavernosal smooth muscle relaxation in the hypercholesterolemic rabbit: a preliminary studyInternational Journal Of Impotence Research, 2000